Risk of an adverse outcome(death or lung transplantation) in relation to risk marker measurements at the onset of intravenous iloprost therapy
| Simple model | Multiple model | |||
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| P̄ra per 1 mmHg increase | 1.05 (1.0–1.09) | 0.042 | ||
| Cardiac index per 0.5 L·min−1·m2 decrease | 1.5 (1.06–2.13) | 0.02 | ||
| PVR per 100 dyn·sec·cm−5 increase | 1.02 (0.99–1.05) | 0.11 | ||
| Sv,O2 per 5% decrease | 1.3 (1.13–1.5) | <0.001 | 1.1 (1.01–1.2) | 0.003 |
| P̄pa per 5 mmHg increase | 1.03 (0.95–1.1) | 0.49 | ||
| 6MWD per 20 m decrease# | 1.0 (0.99–1.01) | 0.6 | ||
| NYHA class¶ | 1.7 (1.2–2.8) | 0.046 | ||
Estimated hazard ratios (HR), 95% confidence intervals (CI), and p-values were calculated by simple and stepwise forward Cox regression analyses. HRs refer to the indicated scales in these variables. P̄ra: mean right atrial pressure; PVR: pulmonary vascular resistance; Sv,O2: mixed venous oxygen saturation; P̄pa: mean pulmonary artery pressure; 6MWD: 6-min walk distance; NYHA: New York Heart Association. #: 6MWD data were available for only 42 patients; ¶: NYHA data were available for only 73 patients.